###begin article-title 0
###xml 63 68 <span type="species:ncbi:10090">mouse</span>
PPARdelta status and mismatch repair mediated neoplasia in the mouse intestine
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 561 565 <span type="species:ncbi:10090">mice</span>
Therapeutic regulation of PPARdelta activity using selective agonists has been proposed for various disorders. However, the consequences of altered peroxisome proliferator-activated receptor delta (PPARdelta) activity in the context of intestinal tumourigenesis remain somewhat unclear. Contradictory evidence suggesting PPARdelta either attenuates or potentiates intestinal neoplasia. To further investigate the PPARdelta dependency of intestinal tumourigenesis, we have analysed the consequences of PPARdelta deficiency upon intestinal neoplasia occurring in mice with impaired mismatch DNA repair.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice deficient for both PPARdelta and the mismatch repair gene Mlh1 were produced and the incidence and severity of intestinal neoplasia recorded.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
No significant differences between the control genotypes and the double mutant genotypes were recorded indicating that deficiency of PPARdelta does not modify impaired mismatch repair induced neoplasia.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 100 103 100 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Apc</italic>
###xml 103 106 103 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Min</italic>
###xml 103 109 103 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Min</italic>/+ </sup>
###xml 109 114 <span type="species:ncbi:10090">mouse</span>
In contrast with the previously observed acceleration of intestinal neoplasia in the context of the ApcMin/+ mouse, PPARdelta deficiency does not alter the phenotype of mismatch repair deficiency. This data supports the notion that PPARdelta is not required for adenoma formation and indicate that any pro-tumourigenic effect of PPARdelta inactivation may be highly context dependent.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 337 338 322 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 711 712 688 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 758 759 735 736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 807 808 784 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 828 829 805 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 852 853 829 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 874 875 851 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 876 877 853 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
Peroxisome proliferator-activated receptors (PPARs) are lipid-activated transcription factors exerting several functions in development and metabolism. There are 3 major PPAR isoforms; alpha,beta/delta and gamma and each has distinct agonist binding properties and different regulation of expression resulting in distinct distributions [1]. The roles for PPARdelta appear diverse and are not fully characterised, but include the regulation of lipid uptake, metabolism, and regulation of proliferation and differentiation within many different cell types. Consequently, the therapeutic regulation of PPARdelta activity using selective agonists has been proposed for many varied disorders including: lung cancer [2], experimental autoimmune encephalomyelitis [3], skin disorders such as psoriasis and cancer [4], type 2 diabetes [5], metabolic syndrome [6] and dyslipidemias [7,8].
###end p 11
###begin p 12
###xml 365 366 349 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 367 369 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 474 476 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 477 479 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 838 840 806 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 930 934 898 902 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Min </sup>
###xml 1060 1062 1024 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1063 1065 1027 1029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1193 1195 1153 1155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1308 1311 1264 1267 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Apc</italic>
###xml 1311 1314 1267 1270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Min</italic>
###xml 1311 1317 1267 1273 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Min</italic>/+ </sup>
###xml 1381 1383 1337 1339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1384 1386 1340 1342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1387 1389 1343 1345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 734 739 <span type="species:ncbi:9606">human</span>
###xml 886 891 <span type="species:ncbi:10090">mouse</span>
###xml 934 939 <span type="species:ncbi:10090">mouse</span>
###xml 1317 1321 <span type="species:ncbi:10090">mice</span>
Although a great deal of evidence exists to show that PPARdelta is potentially important in intestinal tumourigenesis, it is currently unclear whether PPARdelta attenuates or potentiates this condition. Several studies have shown that activation of PPARdelta or increased PPARdelta levels are associated with increased intestinal neoplasia in a variety of tissues [9-13]. Also, two studies have shown that PPARdelta deficiency suppressed or had no role upon tumourigenesis [14,15]. Taken together these analyses suggest that PPARdelta potentiates colon carcinogenesis. However, two independent approaches have recently suggested that PPARdelta expression in vivo is not up-regulated in intestinal adenomas. Firstly a study of matched human tumour and normal intestinal tissues found reduced levels of PPARdelta expression in the tumours [16]. Second several studies using the classical mouse model of intestinal neoplasia (the ApcMin mouse), found either no change, or reduced PPARdelta expression in colonic adenomas compared to normal tissues in this model [17-20], while a recent publication has shown that ligand activation of PPARdelta attenuates chemically induced colon carcinogenesis [20]. Furthermore, it has been demonstrated that PPARdelta deficiency does not suppress intestinal tumourigensis in ApcMin/+ mice, but indeed promotes some aspects of intestinal neoplasia [17,20,21]. These data suggest that PPARdelta attenuates colon carcinogenesis.
###end p 12
###begin p 13
###xml 412 414 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 529 531 525 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 577 579 569 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 614 619 606 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mlh1 </italic>
###xml 630 632 622 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 92 97 <span type="species:ncbi:10090">mouse</span>
###xml 189 193 <span type="species:ncbi:10090">Mice</span>
###xml 453 458 <span type="species:ncbi:9606">human</span>
###xml 571 575 <span type="species:ncbi:10090">mice</span>
###xml 624 628 <span type="species:ncbi:10090">mice</span>
Thus, given the obvious disparity within the published literature, we have utilized another mouse neoplasia model to further investigate the role of PPARdelta in intestinal tumourigenesis. Mice possessing null mutations in the mismatch repair (MMR) gene Mlh1 are prone to develop different types of neoplasia and present with lymphomas and intestinal tumours but show increased mutation in all tissues examined [22]. Likewise, germline mutations in the human MLH1 gene are involved in Hereditary non-polyposis colorectal cancer [23]. We have inter-crossed PPARdelta null mice [24] to the mismatch repair defective Mlh1 null mice [25] and produced cohorts for the different combinations of the genotypes in order to investigate the consequences of impaired MMR induced tumourigenesis in the context of PPARdelta deficiency.
###end p 13
###begin title 14
Methods
###end title 14
###begin p 15
###xml 180 184 176 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPAR</italic>
###xml 189 192 181 184 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 243 247 235 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mlh1</italic>
###xml 247 250 239 242 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 347 351 339 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mlh1</italic>
###xml 351 354 343 346 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 354 358 346 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPAR</italic>
###xml 363 366 351 354 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 366 372 354 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">, Mlh1</italic>
###xml 372 375 360 363 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 375 379 363 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPAR</italic>
###xml 384 387 368 371 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 387 393 371 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">, Mlh1</italic>
###xml 393 396 377 380 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 396 400 380 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPAR</italic>
###xml 405 408 385 388 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
###xml 62 66 <span type="species:ncbi:10090">mice</span>
###xml 174 178 <span type="species:ncbi:10090">mice</span>
###xml 237 241 <span type="species:ncbi:10090">mice</span>
Mice were generated from sixth generation C57BL 6 backcrossed mice. All experiments were performed according to UK Home Office regulations. Inter-crossing the PPARdelta null mice (PPARdelta-/-) to the mismatch repair defective Mlh1 null mice (Mlh1-/-) produced cohorts containing a minimum of 16 animals for each genotype combination of interest (Mlh1-/-PPARdelta+/+, Mlh1-/-PPARdelta+/-, Mlh1-/-PPARdelta-/-). Littermates were genotyped by PCR on DNA from tail biopsy and allowed to age and monitored for signs of intestinal tumours. Animals were harvested when they displayed overt symptoms of disease, and tumour burden was ascertained upon dissection.
###end p 15
###begin title 16
Results and discussion
###end title 16
###begin p 17
###xml 48 52 44 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPAR</italic>
###xml 57 60 49 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 111 115 103 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mlh1</italic>
###xml 115 118 107 110 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 329 330 321 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 381 385 373 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mlh1</italic>
###xml 385 388 377 380 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 388 392 380 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPAR</italic>
###xml 397 401 385 389 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 502 504 490 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 624 628 612 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mlh1</italic>
###xml 628 631 616 619 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 631 635 619 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPAR</italic>
###xml 640 644 624 628 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 648 652 632 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mlh1</italic>
###xml 652 655 636 639 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 655 659 639 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPAR</italic>
###xml 664 668 644 648 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 684 686 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 42 46 <span type="species:ncbi:10090">mice</span>
###xml 105 109 <span type="species:ncbi:10090">mice</span>
###xml 401 405 <span type="species:ncbi:10090">mice</span>
Through inter-crossing the PPARdelta null mice (PPARdelta-/-) to the mismatch repair defective Mlh1 null mice (Mlh1-/-) we produced cohorts containing a minimum of 16 animals for each genotype combination of interest and examined survival, intestinal adenoma multiplicity and tumour size at death for each of the cohorts (Figure 1). We find that, although the mean age at death of Mlh1-/-PPARdelta-/- mice was 248.1 days compared to 203.5 days in controls, this was not statistically different (Figure 1a, p = 0.34 Log-Rank test). Furthermore, the predisposition to lymphomagenesis was not significantly altered between the Mlh1-/-PPARdelta+/+ and Mlh1-/-PPARdelta-/- cohorts (Figure 1b). The possibility remains that there may be subtle effects of PPARdelta deficiency that lie below the detection threshold of the present study, a possibility that would be resolved by a substantially increased cohort analysis.
###end p 17
###begin p 18
###xml 36 42 36 42 <sup xmlns:xlink="http://www.w3.org/1999/xlink">Min/+ </sup>
###xml 42 46 42 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPAR</italic>
###xml 51 55 47 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 156 158 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 159 161 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 162 164 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 270 274 262 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mlh1</italic>
###xml 274 277 266 269 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 277 281 269 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPAR</italic>
###xml 286 290 274 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 294 298 282 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mlh1</italic>
###xml 298 301 286 289 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 301 305 289 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPAR</italic>
###xml 310 314 294 298 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 330 335 314 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c, d</xref>
Contrary to the finding from the APCMin/+ PPARdelta-/- intercross, which indicated that PPARdelta deficiency promotes some aspects of intestinal neoplasia [17,20,21], no significant differences were discovered between either number or size of intestinal adenomas in the Mlh1-/-PPARdelta+/+ and Mlh1-/-PPARdelta-/- cohorts (Figure 1c, d). This was confirmed in both the small intestinal and large intestinal tumours (P > 0.1, Mann Whitney U test), although notably the group sizes in both these analyses were small.
###end p 18
###begin p 19
###xml 28 32 28 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mlh1</italic>
###xml 32 35 32 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 35 39 35 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPAR</italic>
###xml 44 48 40 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 52 56 48 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mlh1</italic>
###xml 56 59 52 55 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 59 63 55 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPAR</italic>
###xml 68 72 60 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 593 595 573 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
To assess the nature of the Mlh1-/-PPARdelta+/+ and Mlh1-/-PPARdelta-/- aberrant intestinal tissues, beta-catenin immunohisochemistry was performed and again no differences were observed between the two genotypes (data not shown). Up-regulation of beta-catenin in large intestinal adenomas was observed in both genotypes. Furthermore in the small intestine, in addition to lesions displaying increased beta-catenin levels, it was also possible to identify a small subset of lesions that maintain normal levels of beta-catenin, a phenomenon previously described within defective MMR intestine [26]. Thus, the induction of dysplastic lesions and the deregulation of beta-catenin in the intestine occurring as a consequence of defective MMR is not dependent upon PPARdelta status and has no requirement for PPARdelta.
###end p 19
###begin p 20
###xml 112 116 108 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mlh1</italic>
###xml 116 120 112 116 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 440 443 432 435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Apc</italic>
###xml 443 446 435 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Min</italic>
###xml 443 448 435 440 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Min</italic>/+</sup>
###xml 448 452 440 444 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPAR</italic>
###xml 457 461 445 449 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 629 632 613 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Apc</italic>
###xml 632 635 616 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Min</italic>
###xml 632 638 616 622 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Min</italic>/+ </sup>
###xml 645 647 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 974 976 950 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1612 1615 1564 1567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Apc</italic>
###xml 1615 1618 1567 1570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Min</italic>
###xml 1615 1620 1567 1572 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Min</italic>/+</sup>
###xml 1672 1678 1624 1630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">per se</italic>
###xml 638 643 <span type="species:ncbi:10090">mouse</span>
We therefore find that loss of PPARdelta does not alter tumour incidence or morphology of tumourigenesis on the Mlh1-/- background. Given that MMR deficiency is considered to lead to a mutator phenotype which thereby increases the rate of mutation of elements of the Wnt pathway, our findings argue that PPARdelta deficiency does not enhance or diminish such a mutator phenotype. By implication, the increased adenoma formation seen in the ApcMin/+PPARdelta-/- mutants may arise through PPARdelta dependent modification of the frequency of gene conversion events that are known to underlie the majority of polyp formation in the ApcMin/+ mouse [27]. Alternatively, subsequent to the gene conversion events, PPARdelta deficiency may alter the resulting cellular signalling/gene expression pathways which permit cell survival and tumour progression. Our data again apparently contradict the observed acceleration of adenoma formation following agonist activation of PPARdelta[11], as this predicts reduced adenoma burden in the absence of PPARdelta. However, PPARdelta deficiency (as assessed through the PPARdelta null mutation) may not necessarily be functionally opposite of ectopic PPARdelta activation as it is possible that any alteration in the levels of PPARdelta activity, whether a reduction or increase, have different consequences dependant on the genetic background or indeed tissue being studied. In terms of evaluating the potential deleterious pro-tumourigenic effect of PPARdelta deficiency, our data suggests that this only accelerates adenoma formation in certain defined genetic settings (e.g. ApcMin/+), and does not generally enhance adenoma formation per se. This genetic dependency may reflect differences in the mutational events occurring in the Mlh1 and Apc mutant backgrounds. By analogy, any potential danger in the therapeutic use of PPARdelta agonists to activate PPARdelta may critically depend upon subtle changes in the underlying genetic predisposition.
###end p 20
###begin title 21
Conclusion
###end title 21
###begin p 22
###xml 108 112 <span type="species:ncbi:10090">mice</span>
In summary, we show that PPARdelta deficiency does not alter either lymphomagenesis or adenoma formation in mice with defective MMR. This data again support the notion that PPARdelta is not required for adenoma formation and indicate that any pro-tumourigenic effect of inactivation may be highly context dependent. Thus, in the context of a defective MMR environment, PPARdelta agonism is unlikely to be pro tumourigenic.
###end p 22
###begin title 23
Competing interests
###end title 23
###begin p 24
The author(s) declare that they have no competing interests.
###end p 24
###begin title 25
Authors' contributions
###end title 25
###begin p 26
KRR, OJS and AJH participated in the animal studies; KRR and OJS carried out the statistical analysis and data presentation; ARC, JMP and AJG conceived the study, and participated in its design and coordination. KRR drafted the manuscript and all authors read and approved the final manuscript.
###end p 26
###begin title 27
Pre-publication history
###end title 27
###begin p 28
The pre-publication history for this paper can be accessed here:
###end p 28
###begin p 29

###end p 29
###begin title 30
Acknowledgements
###end title 30
###begin p 31
###xml 103 107 <span type="species:ncbi:10090">mice</span>
We thank Derek Scarborough and Mark Bishop for technical assistance and Michael Liskay for Mlh1 mutant mice. This work was supported by a programme grant from Cancer Research UK, a grant from the CR-UK New Targets Initiative and the Wales Gene Park.
###end p 31
###begin article-title 32
Peroxisome proliferator-activated receptors: from genes to physiology
###end article-title 32
###begin article-title 33
Peroxisome proliferator-activated receptor delta as a molecular target to regulate lung cancer cell growth
###end article-title 33
###begin article-title 34
Protective effects of a peroxisome proliferator-activated receptor-beta/delta agonist in experimental autoimmune encephalomyelitis
###end article-title 34
###begin article-title 35
PPARbeta/delta selectively induces differentiation and inhibits cell proliferation
###end article-title 35
###begin article-title 36
Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes
###end article-title 36
###begin article-title 37
PPARs: therapeutic targets for metabolic disease
###end article-title 37
###begin article-title 38
Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity
###end article-title 38
###begin article-title 39
Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy
###end article-title 39
###begin article-title 40
PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs
###end article-title 40
###begin article-title 41
Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer
###end article-title 41
###begin article-title 42
Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth
###end article-title 42
###begin article-title 43
###xml 95 100 <span type="species:ncbi:9606">human</span>
Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines
###end article-title 43
###begin article-title 44
Distal bowel selectivity in the chemoprevention of experimental colon carcinogenesis by the non-steroidal anti-inflammatory drug nabumetone
###end article-title 44
###begin article-title 45
###xml 64 69 <span type="species:ncbi:9606">human</span>
Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells
###end article-title 45
###begin article-title 46
Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer
###end article-title 46
###begin article-title 47
Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays
###end article-title 47
###begin article-title 48
###xml 56 61 <span type="species:ncbi:10090">mouse</span>
PPARdelta status and Apc-mediated tumourigenesis in the mouse intestine
###end article-title 48
###begin article-title 49
###xml 45 50 <span type="species:ncbi:10090">mouse</span>
Suppression of tumorigenesis in the Apc(min) mouse: down-regulation of beta-catenin signaling by a combination of tea plus sulindac
###end article-title 49
###begin article-title 50
###xml 75 79 <span type="species:ncbi:10090">mice</span>
###xml 84 89 <span type="species:ncbi:9606">human</span>
###xml 97 105 <span type="species:ncbi:9606">patients</span>
Alteration of gene expression in normal-appearing colon mucosa of APC(min) mice and human cancer patients
###end article-title 50
###begin article-title 51
Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis
###end article-title 51
###begin article-title 52
Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis
###end article-title 52
###begin article-title 53
###xml 50 54 <span type="species:ncbi:10090">mice</span>
Tumour susceptibility and spontaneous mutation in mice deficient in Mlh1, Pms1 and Pms2 DNA mismatch repair
###end article-title 53
###begin article-title 54
Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer
###end article-title 54
###begin article-title 55
###xml 87 92 <span type="species:ncbi:10090">mouse</span>
Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor beta(delta)
###end article-title 55
###begin article-title 56
###xml 15 20 <span type="species:ncbi:10090">mouse</span>
Involvement of mouse Mlh1 in DNA mismatch repair and meiotic crossing over
###end article-title 56
###begin article-title 57
###xml 80 84 <span type="species:ncbi:10090">mice</span>
###xml 132 136 <span type="species:ncbi:10090">mice</span>
Dysregulated expression of -catenin marks early neoplastic change in Apc mutant mice, but not all lesions arising in Msh2 deficient mice
###end article-title 57
###begin article-title 58
A Robertsonian translocation suppresses a somatic recombination pathway to loss of heterozygosity
###end article-title 58
###begin title 59
Figures and Tables
###end title 59
###begin p 60
###xml 0 61 0 61 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Survival of and tumour multiplicity within each of the cohort</bold>
###xml 143 147 143 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mlh1</italic>
###xml 147 150 147 150 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 150 154 150 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPAR</italic>
###xml 159 162 155 158 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 164 168 160 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mlh1</italic>
###xml 168 171 164 167 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 171 175 167 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPAR</italic>
###xml 180 183 172 175 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 189 193 181 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mlh1</italic>
###xml 193 196 185 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 196 200 188 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPAR</italic>
###xml 205 209 193 197 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 301 305 289 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mlh1</italic>
###xml 305 308 293 296 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 308 312 296 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPAR</italic>
###xml 317 321 301 305 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 344 348 328 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mlh1</italic>
###xml 348 351 332 335 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 351 355 335 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPAR</italic>
###xml 360 364 340 344 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 387 391 367 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mlh1</italic>
###xml 391 394 371 374 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 394 398 374 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PPAR</italic>
###xml 403 407 379 383 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 209 213 <span type="species:ncbi:10090">mice</span>
###xml 478 483 <span type="species:ncbi:10090">mouse</span>
###xml 497 501 <span type="species:ncbi:10090">mice</span>
###xml 530 534 <span type="species:ncbi:10090">mice</span>
###xml 566 570 <span type="species:ncbi:10090">mice</span>
###xml 607 611 <span type="species:ncbi:10090">mice</span>
###xml 745 750 <span type="species:ncbi:10090">mouse</span>
Survival of and tumour multiplicity within each of the cohort. Survival of (A), tumour type (B), intestinal adenoma number (C) and size (D) in Mlh1-/-PPARdelta+/+, Mlh1-/-PPARdelta+/-, and Mlh1-/-PPARdelta-/- mice. KaplanMeier plot (A) showing the age of each animal at the time of death: Solid line, Mlh1-/-PPARdelta+/+ (n = 20); dashed line, Mlh1-/-PPARdelta+/- (n = 20); broken line, Mlh1-/-PPARdelta-/- (n = 16). Pie charts (B) indicate the type identified at death in each mouse. Grey slice, mice with lymphoma; white slice, mice with akanthoma; striped slice, mice with dysplastic cysts; black slice, mice with Hemangiosarcomas. Box plots showing the number (combining small and large intestine) (C) or size (D) of intestinal adenomas per mouse at death. Intestinal preparations were collected from animals, fixed and tumours in the small and large intestine were counted and sized (expressed as width by length). Boxes encompass the first quartile (at bottom) to the third quartile (at top) of the data set; the horizontal boxed line represents the median; the asterisks represent outliers.
###end p 60

